Literature DB >> 17482691

Effects of angiotensin II and angiotensin II type 1 receptor blockade on neointimal formation after stent implantation.

Hendrik C Groenewegen1, Pim van der Harst, Anton J M Roks, Hendrik Buikema, Felix Zijlstra, Wiek H van Gilst, Bart J G L de Smet.   

Abstract

BACKGROUND: To evaluate the effect of supraphysiological levels of angiotensin II and selective angiotensin II type 1 receptor (AT1-receptor) blockade on neointimal formation and systemic endothelial function after stent implantation in the rat abdominal aorta.
METHODS: Male Wistar rats were randomized to one of three groups; control (n=8), angiotensin II infusion (n=9, 200 ng/kg/min), or candesartan cilexetil (n=8,AT1-receptor blocker; rats received 14.4 mg kg(-1) day(-1)). Stents were implanted in the abdominal aorta. Histological analyses were performed at 4 weeks. Endothelial function was determined in isolated thoracic aortic rings.
RESULTS: Neointimal area was increased in the angiotensin II treated group versus the control group, 0.88 mm(2)+/-0.21 versus 0.66 mm(2)+/-0.16 (P<0.05). Neointimal thickness was 171 microm+/-44 in angiotensin II treated animals and 120 microm+/-25 in the control group (P<0.05). In addition, endothelial function was attenuated in angiotensin II treated animals (P=0.01). Candesartan cilexetil treatment did not result in reduction of neointimal area and did not reduce neointimal thickness compared to the control group. Candesartan had no effect on endothelial function.
CONCLUSIONS: Supraphysiological levels of angiotensin II aggravates neointimal formation in the stented rat abdominal aorta, and in parallel decreases endothelial function. AT1-receptor blockade does not reduce neointimal formation in rats without supraphysiological angiotensin II levels.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17482691     DOI: 10.1016/j.ijcard.2007.03.127

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  3 in total

Review 1.  Renin-angiotensin system inhibitors in patients with coronary artery disease who have undergone percutaneous coronary intervention.

Authors:  Zhuang Xiao-Dong; Li Fei-Fei; Wen Zhan-Peng; Liao Xin-Xue; Du Zhi-Min
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-05-15

Review 2.  The case for statin therapy in chronic heart failure.

Authors:  Pim van der Harst; Michael Böhm; Wiek H van Gilst; Dirk J van Veldhuisen
Journal:  Clin Res Cardiol       Date:  2007-12-01       Impact factor: 5.460

3.  Imaging in-stent restenosis: an inexpensive, reliable, and rapid preclinical model.

Authors:  Tobias Deuse; Fumiaki Ikeno; Robert C Robbins; Sonja Schrepfer
Journal:  J Vis Exp       Date:  2009-09-14       Impact factor: 1.355

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.